Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Interim results of a multi-center clinical trial evaluating copy number aberrations via shallow whole-genome sequencing (LeukoPrint) in Acute Myeloid Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

YSYongping SongZZZunmin ZhuJWJianyu Weng

Discussion

Loading...

Member takes

Overview

Multi-center trial reports improved detection of copy number aberrations in AML, suggesting enhanced risk stratification and prognostic value.

Key Points

  • This clinical trial aims to evaluate the genomic landscape and clinical significance of copy number aberrations in acute myeloid leukemia.
  • Conducted as a multi-center prospective clinical trial across 13 hospitals in China.
  • Involved 205 newly diagnosed AML patients and utilized shallow whole-genome sequencing via LeukoPrint.
  • Compared the performance of LeukoPrint with conventional karyotyping for CNA detection.
  • Detected 193 CNAs in 87 patients (42.4% of the cohort) using LeukoPrint, outperforming karyotyping (27.3%).
  • Improved risk stratification was achieved with LeukoPrint analysis based on ELN criteria, with some patients reclassified to high-risk.
  • Identified copy-neutral loss of heterozygosity (CN-LOH) in 20.9% of patients, adding insights beyond standard karyotyping.

Cite This Study

Song et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236e032https://doi.org/10.1182/blood-2025-5245
View Full Paper
Ask AI
Bookmark
Share